At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,635 enrolled
Drug / intervention
FF/GW642444 Inhalation Powder +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
HZC102970: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
In Brief
A Phase 3 clinical trial evaluating FF/GW642444 Inhalation Powder and GW642444 Inhalation Powder for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 1,635 participants across 183 sites in 15 countries.
Detailed Summary
The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesArgentina, Australia, Canada, Chile, Denmark, Germany, Italy, Mexico, Netherlands, Peru, South Africa, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2009
First PostedNov 2009
Primary CompletionOct 2011
Study CompletionOct 2011
TodayJul 2026
First PostedNov 23, 2009
Enrollment StartSep 25, 2009
Primary CompletionOct 1, 2011
Study CompletionOct 17, 2011
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 16.6 years ago
Interventions
FF/GW642444 Inhalation Powderdrug
Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
GW642444 Inhalation Powderdrug
Long Acting Beta Agonist(LABA) Inhalation Powder